Related Experiment Video
Updated: Feb 3, 2026

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
CDK4-6 inhibitors in breast cancer: current status and future development
Joan Rou-En Choo1, Soo-Chin Lee1,2
1a Department of Haematology-Oncology , National University Cancer Institute, National University Health System (NUHS) , Singapore , Singapore.
Introduction:
Aberrant cellular proliferation due to dysregulation of the cyclin-dependent kinase (CDK) retinoblastoma (Rb)-pathway occurs in several cancers. Selective inhibition of CDK4/6 is an attractive target particularly in hormone-receptor positive (HR+) metastatic breast cancer (MBC), where it has transformed the treatment of these cancers in recent years. Three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, have been approved for the treatment of HR+, HER2 negative (HER2-) MBC. Areas covered: We reviewed and compared the pharmacology, clinical efficacy, and toxicity profiles of the three CDK4/6 inhibitors and discussed several challenges in the use of these drugs, particularly in identifying biomarkers, optimizing dosing strategies, and finding best combinations with other therapies. Expert opinion: All three CDK4/6 inhibitors have shown remarkable efficacy when added to endocrine therapy in the treatment of HR+/HER2- MBC with consistent improvements in progression-free survival across all phase III trials. As efficacy appears similar between the drugs, differences in toxicities, dosing schedule, and monitoring requirements may influence the choice of CDK4/6 inhibitor. There is a paucity of predictive biomarkers that have been identified thus far, but a few promising biomarkers have been studied in the preclinical setting and results of ongoing clinical studies are awaited to validate their utility.
Insights
Three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) show similar efficacy for hormone-receptor positive metastatic breast cancer. Differences in toxicity and dosing may guide treatment choices, with biomarker research ongoing.
Area of Science:
- Oncology
- Pharmacology
- Translational Medicine
Background:
- Dysregulation of the cyclin-dependent kinase (CDK) retinoblastoma (Rb)-pathway drives aberrant cellular proliferation in various cancers.
- Selective CDK4/6 inhibition is a key therapeutic strategy for hormone-receptor positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC).
- Palbociclib, ribociclib, and abemaciclib are approved CDK4/6 inhibitors for HR+/HER2- MBC treatment.
Purpose of the Study:
- To compare the pharmacology, clinical efficacy, and toxicity profiles of approved CDK4/6 inhibitors.
- To discuss challenges in CDK4/6 inhibitor therapy, including biomarker identification, dosing optimization, and combination strategies.
- To provide an expert opinion on the current landscape and future directions for CDK4/6 inhibitors in HR+/HER2- MBC.
Main Methods:
- Comprehensive literature review of pharmacology, clinical trials, and toxicity data for palbociclib, ribociclib, and abemaciclib.
- Comparative analysis of efficacy (progression-free survival) and safety profiles.
- Discussion of challenges and future research directions based on current evidence.
Main Results:
- All three CDK4/6 inhibitors demonstrate significant efficacy when combined with endocrine therapy for HR+/HER2- MBC, improving progression-free survival.
- Clinical efficacy appears comparable across the three agents.
- Differences in toxicity profiles, dosing schedules, and monitoring requirements exist, potentially influencing clinical selection.
Conclusions:
- CDK4/6 inhibitors have transformed HR+/HER2- MBC treatment with consistent PFS benefits.
- Treatment choice may depend on individual drug toxicity, dosing, and patient monitoring.
- Further research is needed to identify predictive biomarkers and optimize combination therapies for CDK4/6 inhibition.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Sustainable Development
Marcia's Theory of Identity Status
Electrical Current
Current Density
Eddy Currents
Other major applications of eddy currents appear in metal detectors and the braking systems of trains and roller...

